Pivicasiran, a siRNA, is a adiponutrin synthesis reducer.

Pivicasiran sodium, a siRNA, is a adiponutrin synthesis reducer.

Pegpleranib is a pegylated DNA aptamer that selectively binds to PDGF-BB and PDGF-AB homodimers and heterodimers, interrupting the interaction with their associated tyrosine kinase receptors.

Pegpleranib sodium is a pegylated DNA aptamer that selectively binds to PDGF-BB and PDGF-AB homodimers and heterodimers, interrupting the interaction with their associated tyrosine kinase receptors.

Peginterferon alfa-2b (PegIFN a-2b) is an immunomodulator. Peginterferon alfa-2b is a recombinant alfa-2b interferon covalently linked PEG. Peginterferon alfa-2b in decreasing viral DNA in HIV. Peginterferon alfa-2b can be used in research of melanoma and hepatitis C.

P21 saRNA is a small activating RNA (saRNA) targeting the p21 genes. P21 saRNA induce expression of the p21 genes, and targets the p21 promoters at ?322 relative to gene's transcription start site.

Ozisiran, a siRNA, is a hepatitis B virus (HBV) RNA transcript reducer with antiviral activity.

Ozisiran sodium, a siRNA, is a hepatitis B virus (HBV) RNA transcript reducer with antiviral activity.

Opemalirsen is an antisense oligonucleotide targeted to apolipoprotein L1 (APOL1). It is used for the study of Kidney disorders.

Opemalirsen sodium is an antisense oligonucleotide targeted to apolipoprotein L1 (APOL1). It is used for the study of Kidney disorders.

Onvuzosiran, a siRNA, is a prekallikrein synthesis reducer.

Onvuzosiran sodium, a siRNA, is a prekallikrein synthesis reducer.

Obudanersen is an antisense oligonucleotide targeted to ubiquitin protein ligase E3A-antisense transcript (UBE3A-ATS). It is used for the study of Angelman syndrome.

Obudanersen sodium is an antisense oligonucleotide targeted to ubiquitin protein ligase E3A-antisense transcript (UBE3A-ATS). It is used for the study of Angelman syndrome.

Obeversen sodium is an antisense oligonucleotide that inhibits the synthesis of Diacylglycerol acyltransferase 2 (DGAT-2). Obeversen sodium can be used in the research of nonalcoholic fatty liver disease.

S 3578 (sulfate) is a broad-spectrum antibacterial agent, particularly effective against methicillin-resistant Staphylococcus aureus (MRSA) (MIC = 0.78-3.13 μg/mL) and Pseudomonas aeruginosa (MIC = 1.56-6.25 μg/mL). S 3578 (sulfate) can be used in the research of infectious conditions.

SPAA-52 (ammonium) is a low molecular weight protein tyrosine phosphatase (LMW-PTP) inhibitor (IC50 = 4 nM; IC50 = 1.2 nM). SPAA-52 (ammonium) can be used in the research of diabetes mellitus.

FAPI-P8PN is a fibroblast activation protein (FAP) inhibitor (IC50=3.6 nM). FAPI-P8PN is promising for research of FAP-overexpressing solid tumors.

OZO-H is a GST inhibitor. OZO-H is an OZO derivative with potent anti-cancer effects. OZO-H releases JNK1 from GST-JNK1 complex. OZO-H induces JNK1 phosphorylation and activates c-Jun in cancer cells.

OZO-Cl is an OZO derivative. OZO-Cl has anti-cancer activity. OZO-Cl significantly decreases the intracellular glutathion S-transferase Pi (GST) activity. OZO-Cl exhibits cytotoxicity to cancer cell lines, with IC50s of 150 and 120 μmol/L in Panc-1 and K562 cells respectively.

BO 1341 is a PBPs inhibitor and an antipseudomonal semisynthetic cephalosporin. BO 1341 exhibits antibacterial activity against most Gram-negative bacteria, such as Pseudomonas aeruginosa (MIC90: 1.56 μg/mL), Pseudomonas maltophilia (MIC50: 1.56 μg/mL), and Acinetobacter calcoaceticus (MIC90: 3.13 μg/mL) . BO 1341 can be used in the research of infectious diseases.

DQ 2556 is a semi-synthetic cephalosporin antibiotic. DQ-2556 exhibits significant activity against both Gram-positive and Gram-negative bacteria, particularly Gram-positive bacteria and Enterobacteriaceae infections. DQ 2556 exerts its bactericidal effect by interfering with cell division. DQ-2556 has a strong affinity for the penicillin-binding proteins (PBPs) of Escherichia coli: PBP1A/1B (IC₅₀ = 0.57-0.73 μg/mL) and PBP3 (IC₅₀ = 0.088 μg/mL). DQ-2556 demonstrates significant in vivo protective effects. DQ-2556 can be used in the development of injectable cephalosporins.

ME-1036 (CP-5609) is a carbapenem antibiotic. ME-1036 against resistant Gram-positive organisms, including Methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococci (VRE), and ESBL-producing E. coli and K. pneumoniae but is not effective against P. aeruginosa.

Nucresiran is a siRNA that inhibits hepatic synthesis of both wild-type and variant TTR mRNA.

Nucresiran sodium is a siRNA that inhibits hepatic synthesis of both wild-type and variant TTR mRNA.

Nivudirsen is an antisense oligonucleotide that can promote the synthesis of functional dystrophin protein.

Nivudirsen sodium is an antisense oligonucleotide that can promote the synthesis of functional dystrophin protein.

E3 Ligase Ligand-linker Conjugate 179 is an E3 ubiquitinase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 179 can be used to synthesize JV8.

Nelitolimod, a CpG oligonucleotide, is a TLR9 agonist.

Nelitolimod sodium, a CpG oligonucleotide, is a TLR9 agonist.